(financed by the Rudolf Becker Foundation) at the Biomedical Center (BMZ) University of Bonn Medical Center
"Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcionoma of the prostate" by Borkowetz et al. (September 2019) is published in the International Journal of Cancer and demonstrates that immunohistochemical expression of NRP2 is a prognostic marker in prostate cancer. This work is executed in close collaboration with the Department of Urology, University of Dresden Medical Center, Germany.
"Silencing of neuropilins and GIPC1 in pancreatic ductal adenocarcinoma exerts multiple cellular and molecular antitumor effects" by Borchardt et al. (October 2019) is published in Scientific Reports and shows that NRP-2 can be a target for therapy in pancreatic cancer. This work is executed in close collaboration with Achim Aigner of the Rudolf-Boehm-Institute for Pharmacology and Toxicology of the University of Leipzig, Germany.
"Linking NRP2 with EMT and chemoradioresistance in bladder cancer" by Schulz et al. (January 2020) is published in Frontiers in Oncology and demonstrates an important role of NRP2 in bladder cancer progression. This work is executed in close collaboration with the OncoRay, National Center for Radiation Research in Oncology, Dresden, Germany.
"Neuropilin-2 and its transcript variants correlate with clinical outcome in bladder cancer" by Förster et al. (April 2021) is published in "Genes" and demonstrates that NRP2A is an independent prognostic marker in bladder cancer. This work was executed in collaboration with the Department of Urology and Urosurgery, Medical Faculty Mannheim, University of Heidelberg.